New stem cell approach targets functional cure for diabetes - News-Medical
Researchers are exploring immune-engineered stem cell therapies to achieve a functional cure for Type 1 diabetes without the need for immunosuppression.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A new stem cell approach is targeting a functional cure for Type 1 diabetes. This includes the first human trial exploring immune-engineered cell therapy and research aimed at helping transplanted cells thrive.
Coverage from Yahoo Finance and the New England Journal of Medicine (NEJM) highlights long-term data on the durability of hypoimmune-modified islet cell transplantation. News-Medical and Newswise report on the broader effort to establish a functional cure through these modified cells.
Sana Biotechnology is expected to provide further updates on their diabetes cell therapy at the EASD, according to Longevity.Technology.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6m ago.
Quick answers
What is the goal of the new stem cell approach?
The approach targets a functional cure for Type 1 diabetes.
What is unique about the hypoimmune-modified islet cell transplantation?
According to a publication in the NEJM, this method is conducted without the use of immunosuppression.
Which organization is providing an update at EASD?
Sana Biotechnology is heading to EASD with an update on their diabetes cell therapy.
Coverage (6)
- Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D The Manila Times · 1d ago
- First Human Trial Explores Immune-Engineered Cell Therapy for Type 1 Diabetes Bioengineer.org · 1d ago
- Sana Biotech heads to EASD with diabetes cell therapy update Longevity.Technology · 1d ago
- New Research Seeks to Help Transplanted Cells Thrive in Type 1 Diabetes Treatment Newswise · 1d ago
- Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D Yahoo Finance · 1d ago
- New stem cell approach targets functional cure for diabetes News-Medical · 1d ago
Topics
Related trends
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising results from the first human trials.
In October 2024, a team of Chinese researchers at Peking University reported that a 25-year-old woman who had lived with Type 1 diabetes since childhood stopped needing insulin injections within 75 days of receiving an experimental stem cell transplant ge
A Chinese stem cell transplant trial shows promise for Type 1 diabetes patients.
Teplizumab drug to delay type 1 diabetes to be rolled out on the NHS
The NHS will begin rolling out Teplizumab, a disease-modifying therapy designed to delay the onset of type 1 diabetes.